title: Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant.
abstract: We aimed to assess quality of life (QoL) following front-line autologous stem cell transplant (ASCT) and the QoL relationship with rituximab maintenance, in patients with diffuse large B-cell lymphoma. Patients were then randomized to either one weekly rituximab injection for 4 weeks, or observation alone. Patients (n = 269) were given the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaires. Scales for all symptoms exhibited similar temporal patterns, with a marked increase, followed by a plateau after 1 year. The proportion of patients with a clinically significant improvement varied from 6% (constipation) to 56% (fatigue). Age, gender, and previous treatment-induced toxicities were not predictive of variations in QoL. Rituximab significantly reduced pain and symptom severity. Our results for QoL showed that patients experienced rapid recovery after ASCT in all the domains tested. Differences in QoL improvement with time were not connected with rituximab maintenance.
authors.affiliation: Department of Statistics, Université de Caen-Basse Normandie, Caen, France.
authors.forename: Natacha
authors.initials: N
authors.lastname: Heutte
authors.forename: Corinne
authors.initials: C
authors.lastname: Haioun
authors.forename: Pierre
authors.initials: P
authors.lastname: Feugier
authors.forename: Bertrand
authors.initials: B
authors.lastname: Coiffier
authors.forename: Herve
authors.initials: H
authors.lastname: Tilly
authors.forename: Christophe
authors.initials: C
authors.lastname: Ferme
authors.forename: Jean
authors.initials: J
authors.lastname: Gabarre
authors.forename: Franck
authors.initials: F
authors.lastname: Morschhauser
authors.forename: Christian
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mounier
mesh_terms: D000293:Adolescent; D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D011788:Quality of Life; D000069283:Rituximab; D011795:Surveys and Questionnaires; D013997:Time Factors; D014182:Transplantation, Autologous; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab